Jump to content

Pergolide: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Arcadian (talk | contribs)
outline
DumZiBoT (talk | contribs)
m Bot: Converting bare references
Line 33: Line 33:
Pergolide has also been shown to impair associative learning.<ref>{{cite journal |author=Breitenstein C ''et al''. |title=Tonic dopaminergic stimulation impairs associative learning in healthy subjects |journal=Neuropsychopharmacology |volume=31 |issue=11 |pages=2552&ndash;64 |year=2006 |pmid=16880771 |doi=10.1038/sj.npp.1301167}}</ref>
Pergolide has also been shown to impair associative learning.<ref>{{cite journal |author=Breitenstein C ''et al''. |title=Tonic dopaminergic stimulation impairs associative learning in healthy subjects |journal=Neuropsychopharmacology |volume=31 |issue=11 |pages=2552&ndash;64 |year=2006 |pmid=16880771 |doi=10.1038/sj.npp.1301167}}</ref>


On March 30th, 2007, manufacturers of Pergolide agreed to withdraw the drug from the U.S. market after several published studies revealed a link between the drug and increased rates of valvular dysfunction. <ref>http://www.medscape.com/viewarticle/554347?sssdmh=dm1.259053&src=ddd</ref>
On March 30th, 2007, manufacturers of Pergolide agreed to withdraw the drug from the U.S. market after several published studies revealed a link between the drug and increased rates of valvular dysfunction. <ref>[http://www.medscape.com/viewarticle/554347?sssdmh=dm1.259053&src=ddd Log In Problems<!-- Bot generated title -->]</ref>


==References==
==References==

Revision as of 10:26, 4 February 2008

Pergolide
Clinical data
Pregnancy
category
  • B
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding90%
MetabolismExtensively hepatic
Elimination half-life27 hours
Identifiers
CAS Number
PubChem CID
DrugBank
CompTox Dashboard (EPA)
ECHA InfoCard100.241.322 Edit this at Wikidata
Chemical and physical data
FormulaC19H26N2S
Molar mass314.489 g/mol g·mol−1

Pergolide is an ergoline-based dopamine receptor agonist used for the treatment of Parkinson's disease.

Parkinson's disease is associated with low levels of the neurotransmitter dopamine in the brain. Pergolide has some of the same effects as dopamine in the body.

Uses

Pergolide is also used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease, although it has also been used to treat discomfort or pain in the lower extremities that can only be relieved by moving the legs. Pergolide is often used in conjunction with other medicines in the treatment of Parkinson's disease.

Furthermore, pergolide may also be used for veterinary purposes. It is commonly used for the treatment of pituitary pars intermedia hyperplasia or Equine Cushing's Syndrome (ECS) in horses. [2]

Side effects

The drug is in decreasing use, as it was reported in 2003 to be associated with a form of heart disease called cardiac fibrosis.[3] This problem is thought to be due to pergolide's action at the 5-HT2B serotonin receptors of cardiac myocytes, causing proliferative valve disease by the same mechanism as ergotamine, methysergide, fenfluramine, and other serotonin 5-HT2B agonists, including serotonin itself when elevated in the blood in carcinoid syndrome. Pergolide can rarely cause Raynaud's phenomenon. Among similar antiparkinsonian drugs, cabergoline but not lisuride exhibit this same type of serotonin receptor binding.[4] In January, 2007, cabergoline (Dostinex) was reported also to be associated with valvular proliferation heart damage.[5] In March 2007, pergolide was withdrawn from the U.S. market due to serious valvular damage that was shown in two independent studies.[6]

Pergolide has also been shown to impair associative learning.[7]

On March 30th, 2007, manufacturers of Pergolide agreed to withdraw the drug from the U.S. market after several published studies revealed a link between the drug and increased rates of valvular dysfunction. [8]

References

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ Barbara Forney, VMD. "Pergolide For Veterinary Use".
  3. ^ ADRAC (2004). "Cardiac valvulopathy with pergolide". Aust Adv Drug React Bull. 23 (4). {{cite journal}}: Unknown parameter |month= ignored (help) Free full text from the Australian Therapeutic Goods Administration
  4. ^ Jähnichen S, Horowski R, Pertz H. Template:PDFlink Presentation. Retrieved on 2007-03-30.
  5. ^ Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007). "Dopamine agonists and the risk of cardiac-valve regurgitation". N Engl J Med. 356 (1): 29–38. PMID 17202453.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ "MedWatch - 2007 Safety Information Alerts. Permax (pergolide) and generic equivalents". U.S. Food and Drug Administration. March 29, 2007. Retrieved 2007-03-30.
  7. ^ Breitenstein C; et al. (2006). "Tonic dopaminergic stimulation impairs associative learning in healthy subjects". Neuropsychopharmacology. 31 (11): 2552–64. doi:10.1038/sj.npp.1301167. PMID 16880771. {{cite journal}}: Explicit use of et al. in: |author= (help)
  8. ^ Log In Problems